Health ❯Biotechnology ❯Cancer Treatment ❯Immunotherapy

mRNA-based Therapies

BioNTech Moves to Complete $1.25 Billion Curevac Takeover

It is set to boost BioNTech’s mRNA cancer research contingent on securing regulatory approval.

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy